The ImmunAID and EU-MDS consortium studies demonstrated that ASC/NLRP3 inflammasome activation in LR-MDS patients reaches levels comparable to autoinflammatory disorders, with TNF levels predicting disease progression and IL-6/IL-1β correlating with transfusion requirements [96]. The gene discussed is NLRP3; the disease is myelodysplastic syndrome.